Overview

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.